|By PR Newswire||
|April 1, 2014 04:11 AM EDT||
LONDON, April 1, 2014 /PRNewswire/ --
The Biogerontology Research Foundation announces the appointment of Dmitry Kaminskiy to the board of trustees. Mr Kaminskiy was approved to join the board of trustees for his proven commitment and dedication to the main charitable objectives of the BGRF, analytical approach to ageing research and international reach.
Mr Kaminskiy is the managing director of Deep Knowledge Ventures (DKV), a venture capital firm in Hong Kong specializing in seed and early stage financing of companies and research projects advancing research in age-related diseases and regenerative medicine. DKV was one of the first companies to perform the top-down and bottom-up Big Data analysis of and apply machine learning to the large biomedical grant, publication, patent and company databases.
"Ageing and age-related diseases take more lives and cause more pain and suffering annually than all wars and pandemics combined. Ageing knows no borders, regional or national boundaries and we need as many intelligent people as possible to focus on this important challenge. In many developed countries extending productive longevity and helping the elderly stay healthy, active, independent and engaged is no longer an altruistic cause, but a pressing economic necessity. We are happy that Dmitry Kaminskiy, who set an example for many by re-focusing his career from banking and technology entrepreneurship to academic philanthropy and supporting research in ageing, is joining our board of trustees," said Alex Zhavoronkov, PhD, Director of the BGRF.
Before joining Deep Knowledge Ventures, Dmitry Kaminskiy co-founded and helped finance the Center for Biogerontology and Regenerative Medicine (CBRM) in Russia, which employs over 40 full-time and part-time scientists and medical doctors including many young scientists from the Moscow Institute of Physics and Technology and the First Open Institute for Regenerative Medicine for Young Scientists. The CBRM engages in market analytics, publishes industry reports and supports both bioinformatics and laboratory research.
With the addition of the new trustee, the BGRF, which was founded in 2007 to support ageing research, address the challenges of a rapidly ageing population, ameliorate the suffering of the elderly and to reduce the impact of disease on future generations, intends to expand its educational and outreach initiatives by developing and supporting online and mobile resources dedicated to research, training and education in ageing and age-related diseases.
Notes to Editors
About the Biogerontology Research Foundation
The Biogerontology Research Foundation (Charity Commission for England and Wales registration number 1124054) seeks to fill a gap within the research community, whereby the current scientific understanding of the ageing process is not yet being sufficiently exploited to produce effective medical interventions. The BGRF funds research which, building on the body of knowledge about how ageing happens, will develop biotechnological interventions to remediate the molecular and cellular deficits which accumulate with age and which underlie the ill-health of old age.
Addressing ageing damage at this most fundamental level will provide an important opportunity to produce the effective, lasting treatments for the diseases and disabilities of ageing, which are required to improve quality of life in the elderly. The BGRF seeks to use the entire scope of modern biotechnology to attack the changes that take place in the course of ageing, and to address not just the symptoms of age-related diseases but also the mechanisms of those diseases.